Ultragenyx Pharmaceu (RARE)

$25.93 +0.92 (3.68%)
Market Cap 2.46B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 3,454,700
Avg Vol 1,949,398
Day's Range N/A - N/A
Shares Out 98.31M
Stochastic %K 63%
Beta 0.39
Analysts Strong Sell
Price Target $53.35

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
ChromeOnTheWheels
ChromeOnTheWheels May. 7 at 12:05 PM
$RARE $SRPT RARE is back under $30? Need to research but that’s always been a good buy zone for a medium term trade.
0 · Reply
murphylaw
murphylaw May. 7 at 11:53 AM
$SRPT volume is only 106k today. Wait until market opens. Same happened with $RARE yesterday.
1 · Reply
Merlintrader
Merlintrader May. 7 at 5:36 AM
$RARE Ultragenyx Pharmaceutical Inc. (Nasdaq: $RARE): May 2026 Deep Dive https://www.merlintrader.com/ultragenyx-pharmaceuticals-inc-may2026-deepdive/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:12 PM
$RARE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.84 down -17.20% YoY • Reported revenue of $136M down -2.36% YoY • Ultragenyx reaffirms full year 2026 total revenue guidance of $730M to $760M. Ultragenyx expects combined R&D and SG&A expenses to be flat to slightly down versus 2025, on path to profitability in 2027.
1 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ May. 5 at 8:08 PM
$RARE hmmmm it’s a miss
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS May. 5 at 12:12 PM
$RARE mmmmmm I see you
0 · Reply
Pharma3000
Pharma3000 May. 5 at 11:40 AM
$RARE
1 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:29 PM
$RARE Share Price: $24.81 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $4.76 – $5.88 Target Zone: $8.82 – $10.78 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockConsultant
StockConsultant May. 4 at 12:50 PM
$RARE Ultragenyx Pharmaceutical stock, watch for an upside gap breakout at https://stockconsultant.com/?RARE
0 · Reply
Teamtalk2014
Teamtalk2014 May. 1 at 6:56 PM
$MREO Massive undervaluation. $RARE Likely to proceed with UX143, would have been dropped by now if they could not see a path forward. Expecting news on next steps soon. Would not be short.
1 · Reply
Latest News on RARE
Rare disease families find roadmap to drug development at bootcamps

May 7, 2026, 6:30 AM EDT - 2 hours ago

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

May 6, 2026, 4:30 PM EDT - 16 hours ago

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 1 day ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 4:01 PM EDT - 1 day ago

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Apr 29, 2026, 8:00 AM EDT - 8 days ago

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 24, 2026, 4:30 PM EDT - 12 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Apr 3, 2026, 9:43 AM EDT - 4 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Mar 30, 2026, 8:30 AM EDT - 5 weeks ago

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

Mar 25, 2026, 4:10 PM EDT - 6 weeks ago

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Mar 12, 2026, 1:35 PM EDT - 7 weeks ago

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Mar 12, 2026, 8:47 AM EDT - 2 months ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 11:00 AM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 12:00 PM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 2 months ago

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 2 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 2 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 2 months ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 2 months ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Why Is Ultragenyx Stock Sinking Friday?

Feb 13, 2026, 1:21 PM EST - 2 months ago

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Feb 12, 2026, 5:00 PM EST - 2 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 2 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

Feb 9, 2026, 4:30 PM EST - 3 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 3 months ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 3 months ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 3 months ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 3 months ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 4 months ago

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 4 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 4 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 4 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Dec 30, 2025, 9:52 AM EST - 4 months ago

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 4 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 4 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 4 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 12:55 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:15 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 6 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 6 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 6 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 7 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 8 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 9 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2025

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 9 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

ChromeOnTheWheels
ChromeOnTheWheels May. 7 at 12:05 PM
$RARE $SRPT RARE is back under $30? Need to research but that’s always been a good buy zone for a medium term trade.
0 · Reply
murphylaw
murphylaw May. 7 at 11:53 AM
$SRPT volume is only 106k today. Wait until market opens. Same happened with $RARE yesterday.
1 · Reply
Merlintrader
Merlintrader May. 7 at 5:36 AM
$RARE Ultragenyx Pharmaceutical Inc. (Nasdaq: $RARE): May 2026 Deep Dive https://www.merlintrader.com/ultragenyx-pharmaceuticals-inc-may2026-deepdive/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:12 PM
$RARE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.84 down -17.20% YoY • Reported revenue of $136M down -2.36% YoY • Ultragenyx reaffirms full year 2026 total revenue guidance of $730M to $760M. Ultragenyx expects combined R&D and SG&A expenses to be flat to slightly down versus 2025, on path to profitability in 2027.
1 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ May. 5 at 8:08 PM
$RARE hmmmm it’s a miss
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS May. 5 at 12:12 PM
$RARE mmmmmm I see you
0 · Reply
Pharma3000
Pharma3000 May. 5 at 11:40 AM
$RARE
1 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:29 PM
$RARE Share Price: $24.81 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $4.76 – $5.88 Target Zone: $8.82 – $10.78 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockConsultant
StockConsultant May. 4 at 12:50 PM
$RARE Ultragenyx Pharmaceutical stock, watch for an upside gap breakout at https://stockconsultant.com/?RARE
0 · Reply
Teamtalk2014
Teamtalk2014 May. 1 at 6:56 PM
$MREO Massive undervaluation. $RARE Likely to proceed with UX143, would have been dropped by now if they could not see a path forward. Expecting news on next steps soon. Would not be short.
1 · Reply
LaGoodie
LaGoodie Apr. 28 at 5:41 PM
$RARE
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 23 at 4:49 AM
$RARE RSI: 70.85, MACD: 0.8382 Vol: 1.98, MA20: 22.81, MA50: 22.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
shortvolume
shortvolume Apr. 17 at 11:44 PM
$RARE unintelligent bears short while our algorithm signals alpha.
0 · Reply
Biologics
Biologics Apr. 12 at 12:59 PM
My recent article on $RARE https://seekingalpha.com/article/4890075-ultragenyx-pharmaceutical-the-market-is-overlooking-2026-catalysts?source=copy_to_clipboard
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 9 at 8:36 PM
$RARE Phase 3 Enh3ance hits primary endpoint: 18% ammonia reduction vs placebo (p=0.018) with 27% scavenger taper. One placebo death, zero treated. 64-week treatment burden data H1 2027 — that's the BLA readout. Pricing at $2.5-3.2M justified against $500K-1M/yr Ravicti. TAM ~250-300 patients limits peak revenue but PRV ($95-110M) de-risks near-term. Read more: www.clinicaltrialsdaily.com/ultragenyx-dtx301-phase-3-otc-deficiency/
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 1:42 PM
$OMER there's no way $RARE IS WORTH MORE THAN THIS COMPANY
0 · Reply
QuantInsider
QuantInsider Apr. 3 at 2:08 AM
$RARE popping off today, up 4.81% and 12.25% over the past 5 days FDA's nod on the UX111 BLA and UX016 IND is a big deal, driving that momentum Options flow is all about those May $20 puts, around 636 contracts, no sweeps Traders seem to be hedging their bets, not going all in on upside Feels like a cautious vibe, keeping an eye on volatility after the spike Might be smart to stick with defined risk plays here
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 2:20 PM
$RARE $LPCN
0 · Reply
jaykza
jaykza Apr. 2 at 1:46 PM
$ABEO Double good news a $RARE UX-111 BLA submission accepted as well.
2 · Reply
TwongStocks
TwongStocks Apr. 2 at 12:32 PM
$RARE Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) https://www.globenewswire.com/news-release/2026/04/02/3267337/20739/en/Ultragenyx-Announces-U-S-FDA-Acceptance-of-BLA-Resubmission-for-UX111-AAV-Gene-Therapy-to-Treat-Sanfilippo-Syndrome-Type-A-MPS-IIIA.html • PDUFA action date set for September 19, 2026
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 2:33 AM
$RARE Share Price: $20.93 Contract Selected: Nov 20, 2026 $20 Calls Buy Zone: $5.61 – $6.93 Target Zone: $10.43 – $12.74 Potential Upside: 76% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockBen4444
StockBen4444 Mar. 31 at 4:41 PM
$RARE can i see a bull flag?
0 · Reply